Xencor

Xencor, based in Pasadena and listed as XNCR, is an antibody engineering company built on its XmAb Fc technology, developing 2+1 format T-cell engagers for kidney cancer, targeting ENPP3, and for ovarian and germ-cell tumours, targeting Claudin 6. XmAb819, an ENPP3 by CD3 engager, is in clear-cell renal cell carcinoma with a pivotal study planned for 2027, XmAb541, a Claudin 6 by CD3 engager, has produced confirmed partial responses in ovarian and germ-cell tumours, and the XmAb Fc technology is licensed into several approved antibodies. OnCo links it to renal cell carcinoma and ovarian cancer, to T-cell engagers and bispecific antibodies, and to CD3 as a target. Whether T-cell engagers can work in solid tumours without unacceptable toxicity is the question its 2+1 format is designed to answer. The T-cell engager page carries the field.